Boston Scientific's Q3 Sales Soar 20% Amid Aggressive M&A Push

TL;DR

**BSX is crushing it with massive sales and profit growth, fueled by smart acquisitions – buy the dip if you can find one.**

AI Summary

BOSTON SCIENTIFIC CORP (BSX) reported robust financial performance for the three and nine months ended September 30, 2025. Net sales for the three months increased by 20.3% to $5.065 billion from $4.209 billion in the prior year, while net sales for the nine months rose by 21.3% to $14.788 billion from $12.186 billion. Net income attributable to common stockholders surged by 61.0% to $755 million for the three months, up from $469 million, and by 72.8% to $2.226 billion for the nine months, compared to $1.288 billion. Diluted EPS also saw significant growth, reaching $0.51 for the quarter and $1.49 for the nine-month period. The company actively pursued strategic acquisitions in 2025, including Anrei Medical for $182 million, SoniVie for $362 million upfront, Intera Oncology for $172 million, Bolt Medical for $475 million upfront, and Cortex, Inc. for $239 million upfront, expanding its Cardiology, Endoscopy, Peripheral Interventions, and Neuromodulation divisions. Cash and cash equivalents increased significantly to $1.275 billion as of September 30, 2025, from $414 million at December 31, 2024, reflecting strong operating cash flow of $3.170 billion for the nine months.

Why It Matters

This strong performance, particularly the 20.3% net sales growth and 61.0% net income increase for the quarter, signals robust demand for Boston Scientific's medical devices and effective integration of recent acquisitions. For investors, this indicates a healthy growth trajectory and potential for continued shareholder value appreciation, especially with the strategic expansion into high-growth areas like chronic pain and cardiovascular treatments. Employees benefit from a growing company with expanded market reach and product portfolios. Customers gain access to a broader range of innovative medical solutions, enhancing patient care. In the competitive medical technology landscape, BSX's aggressive M&A strategy, exemplified by the Nalu Medical acquisition agreement, positions it to strengthen its market share against rivals like Medtronic and Abbott Laboratories.

Risk Assessment

Risk Level: medium — While financial performance is strong, the company's aggressive acquisition strategy, with payments for acquisitions totaling $1.504 billion for the nine months ended September 30, 2025, introduces integration risks and potential for goodwill impairment. The accumulated other comprehensive loss, net of tax, shifted from a gain of $275 million at December 31, 2024, to a loss of $689 million at September 30, 2025, primarily due to foreign currency translation adjustments of -$719 million and net changes in derivative financial instruments of -$238 million for the nine months, indicating exposure to market volatility.

Analyst Insight

Investors should consider holding or initiating a position in BSX, given its strong revenue and net income growth, coupled with strategic acquisitions that promise future expansion. Monitor the integration progress of recent acquisitions like Nalu Medical and SoniVie, and keep an eye on foreign currency fluctuations, as these could impact future comprehensive income.

Financial Highlights

revenue

$5.065B

operating Margin

20.7%

net Income

$755M

eps

$0.51

gross Margin

69.9%

cash Position

$1.275B

revenue Growth

+20.3%

Revenue Breakdown

Key Numbers

• $5.065B — Net sales for Q3 2025 (Increased by 20.3% from $4.209 billion in Q3 2024)
• $14.788B — Net sales for nine months ended Sept 30, 2025 (Increased by 21.3% from $12.186 billion in the prior year period)
• $755M — Net income attributable to common stockholders for Q3 2025 (Increased by 61.0% from $469 million in Q3 2024)
• $2.226B — Net income attributable to common stockholders for nine months ended Sept 30, 2025 (Increased by 72.8% from $1.288 billion in the prior year period)
• $0.51 — Diluted EPS for Q3 2025 (Increased from $0.32 in Q3 2024)
• $1.49 — Diluted EPS for nine months ended Sept 30, 2025 (Increased from $0.87 in the prior year period)
• $1.275B — Cash and cash equivalents as of Sept 30, 2025 (Increased from $414 million at December 31, 2024)
• $3.170B — Cash provided by operating activities for nine months ended Sept 30, 2025 (Increased from $1.979 billion in the prior year period)
• $1.504B — Payments for acquisitions of businesses, net of cash acquired, for nine months ended Sept 30, 2025 (Reflects significant M&A activity)
• -$689M — Accumulated other comprehensive income (loss), net of tax, as of Sept 30, 2025 (Shifted from a gain of $275 million at December 31, 2024, primarily due to foreign currency translation adjustments)

Key Players & Entities

• BOSTON SCIENTIFIC CORP (company) — registrant
• Nalu Medical, Inc. (company) — privately held medical technology company being acquired
• Anrei Medical (HZ) Co., Ltd. (company) — acquired company specializing in minimally invasive gastroenterology devices
• SoniVie Ltd. (company) — acquired medical device company with TIVUS Intravascular Ultrasound System
• Intera Oncology, Inc. (company) — acquired medical device company providing Intera 3000 Hepatic Artery Infusion Pump
• Bolt Medical, Inc. (company) — acquired developer of intravascular lithotripsy platform
• Cortex, Inc. (company) — acquired medical technology company focused on atrial fibrillation diagnostic mapping
• New York Stock Exchange (regulator) — exchange where BSX common stock is registered
• U.S. Food and Drug Administration (regulator) — approves medical devices and drugs
• Acotec Scientific Holdings Limited (company) — majority stake investment consolidated by BSX

FAQ

Risk Factors

• Regulatory Approval Delays [high — regulatory]: The company's ability to introduce new products and expand into new markets is contingent on obtaining timely regulatory approvals from bodies like the FDA and EMA. Delays or rejections can significantly impact revenue forecasts and competitive positioning.
• Intense Competition [high — market]: The medical device industry is highly competitive, with numerous players vying for market share. Competitors may introduce innovative technologies or engage in aggressive pricing strategies, potentially eroding BSX's market position and profitability.
• Supply Chain Disruptions [medium — operational]: Global supply chain vulnerabilities, as experienced in recent years, pose a risk to the timely manufacturing and delivery of BSX's products. Disruptions can lead to increased costs and lost sales opportunities.
• Acquisition Integration Risks [medium — financial]: The company's strategy involves significant M&A activity, with $1.504 billion spent on acquisitions in the nine months ended September 30, 2025. Failure to successfully integrate acquired businesses could result in unachieved synergies, operational inefficiencies, and financial underperformance.
• Product Liability and Litigation [medium — legal]: As a manufacturer of medical devices, BSX faces inherent risks related to product liability claims and potential litigation. Adverse legal outcomes could result in significant financial penalties and reputational damage.
• Foreign Currency Fluctuations [medium — financial]: The company's international operations expose it to foreign currency exchange rate fluctuations. A significant shift in exchange rates, as indicated by the -$719 million foreign currency translation adjustment in other comprehensive income for the nine months, can negatively impact reported financial results.
• Post-Market Surveillance and Recalls [medium — regulatory]: Medical devices are subject to ongoing post-market surveillance. Issues identified after a product is on the market could lead to recalls, regulatory actions, and damage to the company's reputation.
• Intellectual Property Protection [low — operational]: Protecting its intellectual property is crucial for BSX's competitive advantage. Infringement by competitors or challenges to its patents could diminish the value of its innovations.

Industry Context

Boston Scientific operates in the highly dynamic and competitive medical technology industry. Key trends include the increasing demand for minimally invasive procedures, advancements in robotics and AI-driven diagnostics, and a growing focus on personalized medicine. The industry is characterized by significant R&D investment, strategic M&A to gain market access and technological capabilities, and a complex regulatory environment.

Regulatory Implications

The medical device sector is heavily regulated by agencies such as the FDA in the U.S. and the EMA in Europe. Compliance with stringent quality standards, pre-market approval processes, and post-market surveillance requirements are critical. Any failure to adhere to these regulations can result in product recalls, fines, and market access restrictions, directly impacting financial performance.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: End of Q3 2025 and Nine Months Reporting Period — Provided updated financial performance, showcasing significant revenue and net income growth, and substantial M&A activity.
• 2025-12-31: Previous Fiscal Year End — Benchmark for year-over-year comparisons, particularly for cash and cash equivalents which increased from $414 million.

Glossary

Amortization expense

The systematic allocation of the cost of an intangible asset over its useful life. For BSX, this includes amortization of acquired intangible assets. (A non-cash expense that reduces operating income. BSX reported $225 million for Q3 2025 and $669 million for the nine months.)

Intangible asset impairment charges

A charge taken when the carrying value of an intangible asset on the balance sheet is deemed to be unrecoverable, exceeding its fair value. (BSX recorded $0 for Q3 2025 and $46 million for the nine months, a significant decrease from $276 million in the prior year's nine-month period, indicating improved asset values or reduced write-downs.)

Contingent consideration

An obligation to transfer additional consideration (e.g., cash or stock) to an seller of a business contingent upon the occurrence of certain future events. (BSX reported a net expense of $11 million for Q3 2025 and $11 million for the nine months, a change from a net benefit of ($23) million and ($4) million respectively in the prior year, reflecting adjustments to acquisition-related liabilities.)

Other comprehensive income (loss)

Unrealized gains or losses that bypass the income statement but affect equity. Includes items like foreign currency translation adjustments and unrealized gains/losses on certain investments. (BSX reported a net loss of ($957) million for the nine months ended Sept 30, 2025, primarily driven by foreign currency translation adjustments of ($719) million, impacting total equity.)

Weighted-average shares outstanding — diluted

The number of shares of common stock that would have been outstanding if all convertible securities, options, and warrants had been exercised, used to calculate diluted EPS. (BSX's diluted shares outstanding were 1,495.5 million for Q3 2025 and 1,494.0 million for the nine months, crucial for EPS calculations.)

Noncontrolling interests

The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership stake of outside shareholders. (BSX reported minimal impact from noncontrolling interests, with net income attributable to them being ($0) million for Q3 2025 and ($4) million for the nine months.)

Year-Over-Year Comparison

Boston Scientific Corporation has demonstrated substantial year-over-year improvement in its financial performance. Net sales for the nine months ended September 30, 2025, grew by 21.3% to $14.788 billion, compared to $12.186 billion in the prior year. Net income attributable to common stockholders saw an even more dramatic increase of 72.8%, reaching $2.226 billion from $1.288 billion. Diluted EPS also significantly improved, rising from $0.87 to $1.49. The company's cash position has strengthened considerably, with cash and cash equivalents more than tripling from $414 million at the end of 2024 to $1.275 billion as of September 30, 2025, supported by robust operating cash flow. A notable shift occurred in accumulated other comprehensive income (loss), which moved from a gain of $275 million to a loss of -$689 million, primarily due to foreign currency translation adjustments.

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share BSX New York Stock Exchange

Filing Documents

• bsx-20250930.htm (10-Q) — 2193KB
• exhibit311-ceo302q32025.htm (EX-31.1) — 20KB
• exhibit312-cfo302q32025.htm (EX-31.2) — 20KB
• exhibit321-ceo906q32025.htm (EX-32.1) — 11KB
• exhibit322-cfo906q32025.htm (EX-32.2) — 11KB
• 0000885725-25-000050.txt ( ) — 12124KB
• bsx-20250930.xsd (EX-101.SCH) — 63KB
• bsx-20250930_cal.xml (EX-101.CAL) — 103KB
• bsx-20250930_def.xml (EX-101.DEF) — 343KB
• bsx-20250930_lab.xml (EX-101.LAB) — 788KB
• bsx-20250930_pre.xml (EX-101.PRE) — 591KB
• bsx-20250930_htm.xml (XML) — 2486KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 40 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 59 ITEM 4.

Controls and Procedures

Controls and Procedures 60 PART II OTHER INFORMATION 61 ITEM 1.

Legal Proceedings

Legal Proceedings 61 ITEM 1A.

Risk Factors

Risk Factors 61 ITEM 5. Other Information 61 ITEM 6. Exhibits 61 SIGNATURE 63 2 Table of Content s PART I FINANCIAL INFORMATION

CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended September 30, Nine Months Ended September 30, (in millions, except per share data) 2025 2024 2025 2024 Net sales $ 5,065 $ 4,209 $ 14,788 $ 12,186 Cost of products sold (excluding amortization expense) 1,523 1,312 4,613 3,791 Gross profit 3,542 2,897 10,175 8,395 Operating expenses: Selling, general and administrative expenses 1,741 1,562 5,053 4,372 Research and development expenses 514 407 1,483 1,156 Royalty expense 12 5 40 24 Amortization expense 225 205 669 631 Intangible asset impairment charges 0 — 46 276 Contingent consideration net expense (benefit) 11 ( 23 ) 11 ( 4 ) Restructuring net charges (credits) ( 8 ) 8 85 12 2,494 2,164 7,387 6,467 Operating income (loss) 1,048 733 2,788 1,928 Other income (expense): Interest expense ( 87 ) ( 79 ) ( 259 ) ( 225 ) Other, net ( 23 ) 14 156 ( 7 ) Income (loss) before income taxes 939 669 2,685 1,697 Income tax expense (benefit) 183 200 463 413 Net income (loss) 755 468 2,222 1,284 Net income (loss) attributable to noncontrolling interests ( 0 ) ( 0 ) ( 4 ) ( 4 ) Net income (loss) attributable to Boston Scientific common stockholders $ 755 $ 469 $ 2,226 $ 1,288 Net income (loss) per common share — basic $ 0.51 $ 0.32 $ 1.50 $ 0.88 Net income (loss) per common share — diluted $ 0.51 $ 0.32 $ 1.49 $ 0.87 Weighted-average shares outstanding Basic 1,481.7 1,472.7 1,479.6 1,470.6 Diluted 1,495.5 1,487.4 1,494.0 1,484.5 Refer to notes to the unaudited consolidated financial statements. Amounts may not add due to rounding. 3 Table of Content s BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) Three Months Ended September 30, Nine Months Ended September 30, (in millions) 2025 2024 2025 2024 Net income (loss) $ 755 $ 468 $ 2,222 $ 1,284 Other comprehensive i